SeraCare Life Sciences, Inc. (NASDAQ: SRLS) announced today that the
Company has added five new, differentiated products to its portfolio to
meet the needs of SeraCare’s growing customer base in the life sciences
industry.
Susan Vogt, President and Chief Executive Officer stated, “SeraCare
ended 2009 with more than 250 new customers across the life sciences
industry worldwide and we are pleased to kick off 2010 with the
introduction of a variety of products specifically designed to meet the
needs of our expanding customer base. The latest additions to our
product portfolio continue to set SeraCare apart as a leading provider
of high quality products and services that facilitate the discovery,
development and manufacturing of drugs and diagnostics.”
SeraCare’s new products include:
-
A set of specific controls for infectious disease testing that offer
the most comprehensive assay coverage in the industry for the Abbott
ARCHITECT testing platform. SeraCare’s new controls set the standard
for accuracy, delivering customers the potential for lower cost, more
efficient testing and improved error detection in the laboratory.
-
ACCURUN® 1 Series 2700 Multi-Marker
Positive Control allows end-users to develop a more efficient
quality control program by offering a single product for multiple
antigens related to various types of HIV, hepatitis, cytomegalovirus
and T-lymphotropic virus.
-
ACCURUN® 106 Series 1000 Positive Control
provides positive diagnostic control detection of the HIV type 1
antigen and is critical for monitoring the performance of HIV tests
that allow for the early detection of HIV infection.
-
Two differentiated, cryopreserved human peripheral blood mononuclear
cell (PBMC) products that serve as tools in life science research and
drug development. SeraCare’s PBMCs are utilized in immune response
monitoring, cytokine production, gene expression analysis,
toxicity/immunotoxicity screening, cytotoxicity assays, stimulation
and proliferation studies, and biomarker identification and
characterization.
-
AccuCell™ Human PBMC-Basic and AccuCell™
Human PBMC-Characterized products both offer off-the-shelf
flexibility. SeraCare’s ability to produce PBMCs in large lots offers
customers better assay-to-assay consistency, the option to use
lot-specific cells across multiple test sites and the ability to
compare assays from multiple time points across multiple preclinical
studies or clinical trials.
-
A multiplex viral research reagent for use with assays that detect and
differentiate influenza viruses. This new product is the only ready to
use reagent on the market for assessing and monitoring the performance
of influenza assays.
-
ACCUTYPE™ H1N1 is designed to perform
on FDA-issued Emergency Use Authorized Medical Devices that detect the
H1N1 influenza virus as well as other assays that detect H1N1 viral
RNA.